neurodegenerative conditions
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
July 14, 2025Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …
Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases
May 9, 2025Research and Development Galimedix Therapeutics, Neurology, Opthalmology, R&D, clinical trial, neurodegenerative conditions
Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part of a phase 1 study …
Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
May 7, 2025Mergers and Acquisitions Alchemab Therapeutics, Corporate, Eli Lilly and Company, Immunology, M&A, als, immunology, neurodegenerative conditions
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, its …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEO
October 13, 2026
Tridem begins phase Ib trial of Parkinson’s disease vaccine
October 13, 2026
Trio become latest Symbiosis commercial additions
October 12, 2026
UK immunoglobulin supply faces growing pressure, report warns
October 12, 2026
